Coloplast A/S COLO-B.CO
Composite 52/100; the shares have moved about 29% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 35/100 — a moderate mark against it.
Quality ranks 65/100 — a moderate point in its favour. Income ranks 59/100 — a slight point in its favour. Balance-sheet strength ranks 55/100 — a slight point in its favour.
Momentum ranks 35/100 — a moderate mark against it. Growth ranks 44/100 — a slight mark against it. Valuation ranks 47/100 — a slight mark against it.
What the company does Coloplast A/S develops and sells intimate healthcare products across Chronic Care, Continence Care, and Wound Dressings segments, including ostomy and catheter solutions.
Key financials Coloplast reports ROE 14.1%, ROA 9.9%, and ROCE 17.2%, with gross margins 67.5% and net margins 7.5%. Revenue grew 2.2% while EPS surged 33.9%. Dividend yield is 5.5% with a 246.2% payout ratio.
Stock health Sideravia scores show strong quality (66.2) but weak momentum (29.0). Piotroski F-Score is 6/9, Altman Z is 3.25, and debt ratios are elevated (Debt/Equity 1.89, Net debt/EBITDA 2.72).
Price vs fair value The stock trades at a **PREMIUM of 28.60%** to our fair-value estimate (310.80) and a **discount of 5.25%** to the 12-month target (458.24). - High valuation metrics: P/E 46.14, P/B 7.08, EV/EBITDA 13.31 (Valuation 41.9/100). - Strong profitability but weak momentum: 12m return -25.89%, RSI 66.40. - High dividend yield (5.5%) but unsustainable payout ratio (246.2%).
Looking forward Forward P/E (14.95) and PEG (0.07) suggest undemanding near-term multiples, but growth (50.5) and momentum (29.0) trail peers. Analysts (n=21) see 5.25% upside to 458.24.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.